Skip to Content

Viatris Inc VTRS

Morningstar Rating
$12.15 −0.15 (1.22%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Viatris Earnings: Firm Wraps Up 2023 on a Solid Note; New Partnership Bolsters Pipeline

No-moat Viatris reported fourth-quarter earnings that came in largely in line with our expectations. Total sales of $3.8 billion were down 1% year over year. The Biocon divestiture, which closed November 2022, posed certain difficulties in comparison but resilient branded business in both developed and robust emerging markets offset most of the headwinds. We maintain our fair value estimate of $13 per share, as minor adjustments to our near-term assumptions didn't affect our valuation.

Price vs Fair Value

VTRS is trading at a 5% discount.
Price
$12.29
Fair Value
$54.00
Uncertainty
Very High
1-Star Price
$17.77
5-Star Price
$7.40
Economic Moat
Jrkv
Capital Allocation
Dlnhtwvq

Bulls Say, Bears Say

Bulls

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power.

Bears

Base business erosion will continue to persist in developed markets and act as headwinds that Viatris must try to offset with new product launches.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VTRS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$12.30
Day Range
$12.1212.39
52-Week Range
$8.7513.61
Bid/Ask
$12.13 / $12.15
Market Cap
$14.71 Bil
Volume/Avg
2,644 / 10.4 Mil

Key Statistics

Price/Earnings (Normalized)
4.11
Price/Sales
0.96
Dividend Yield (Trailing)
3.91%
Dividend Yield (Forward)
3.91%
Total Yield
5.58%

Company Profile

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Value
Total Number of Employees
38,000

Competitors

Valuation

Metric
VTRS
TEVA
NVS
Price/Earnings (Normalized)
4.115.1115.01
Price/Book Value
0.711.964.48
Price/Sales
0.960.924.58
Price/Cash Flow
4.5110.1714.66
Price/Earnings
VTRS
TEVA
NVS

Financial Strength

Metric
VTRS
TEVA
NVS
Quick Ratio
0.780.540.88
Current Ratio
1.601.021.16
Interest Coverage
5.360.3910.94
Quick Ratio
VTRS
TEVA
NVS

Profitability

Metric
VTRS
TEVA
NVS
Return on Assets (Normalized)
7.36%6.70%12.15%
Return on Equity (Normalized)
17.56%39.00%27.10%
Return on Invested Capital (Normalized)
10.13%13.54%17.72%
Return on Assets
VTRS
TEVA
NVS
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AZxcjv$91.5 Bil
MKKGY
Merck KGaA ADRDzfmvyg$74.9 Bil
HLN
Haleon PLC ADRFgmfp$36.8 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRTjy$14.7 Bil
RDY
Dr Reddy's Laboratories Ltd ADRDqvw$12.9 Bil
CTLT
Catalent IncCpcwjdr$10.5 Bil
PRGO
Perrigo Co PLCLtpd$3.6 Bil
CURLF
Curaleaf Holdings IncKcmg$3.6 Bil
PBH
Prestige Consumer Healthcare IncZkrcck$3.5 Bil

Sponsor Center